Kineta Programs Named “Top Projects” Second Year Running

Leading pharmaceutical industry publisher Elsevier / Windhover honors both Kineta Autoimmune and Antiviral Drug Development Programs

SEATTLE--(BUSINESS WIRE)-- Kineta’s two lead drug development programs will be honored by the pharmaceutical industry this week for their scientific distinction and likelihood to rapidly progress to high-value partnering deals. Both ShK-186 and r-OAS1, Kineta’s autoimmune and antiviral programs, were named among the “Top Projects to Watch” by Windhover and Elsevier Business Intelligence companies.

Kineta President and C.E.O., Charles L. Magness, Ph.D., will provide an overview presentation on each program to industry peers at the Therapeutic Area Partnerships conference in Boston on Thursday, December 1st.

“The Kineta team saw early on the tremendous potential of both ShK-186 and r-OAS1 for future patients and Kineta investors. We appreciate the significance of inclusion in this annual list of innovative programs and thank the organizers,” said Dr. Magness.

The criteria for selection to the “Top Projects” list were large market, unmet human need, scientific excellence, diversity of indications and multi-level partnering potential. "Many of the companies we selected in the past have gone on to do big deals, and we expect the same from this year's companies," said David Cassak, VP of Content, for Elsevier Business Intelligence's publications.

For more information on today’s announcement contact Meg O’Conor, Director of Corporate Communications and Investor Relations, [email protected] or 206-251-8638. The entire list of “Top Projects to Watch” is available at www.tapartnerships.com.

Kineta, Inc. is a Seattle-based privately held biotechnology company specializing in clinical advancement of immunotherapeutic drug candidates. Our world class scientists are pioneers in developing life-changing classes of drugs that harness the power of the immune system to fight disease. Kineta seeks to improve the lives of millions of people suffering from autoimmune and viral diseases. Our progressive business model focuses on targeting unmet medical needs and rapid achievement of important clinical milestones. For more information on Kineta, Inc. visit our website, www.Kinetabio.com.

NOTICE:

This document contains certain forward-looking statements, including without limitation statements regarding potential partnership transactions and investor returns. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.



CONTACT:

Kineta, Inc.
Meg O’Conor, 206-251-8638
[email protected]

KEYWORDS:   United States  North America  Massachusetts  Washington

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.